Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omigapil - Santhera Pharmaceuticals

Drug Profile

Omigapil - Santhera Pharmaceuticals

Alternative Names: CGP 3466; CGP 3466 maleate; CGP 3466B; SNT 317; TCH 346

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; Santhera Pharmaceuticals
  • Class Antiparkinsonians; Neuroprotectants; Oxepins; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Glyceraldehyde 3 phosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Muscular dystrophies
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Muscular dystrophies
  • Discontinued Amyotrophic lateral sclerosis; Motor neuron disease; Parkinson's disease

Most Recent Events

  • 05 Apr 2018 Interim pharmacokinetic and adverse events data from the phase I CALLISTO trial in Muscular-dystrophies released by Santhera Pharmaceuticals
  • 05 Apr 2018 Santhera Pharmaceuticals completes the phase I CALLISTO trial in Muscular-dystrophies in USA (NCT01805024)
  • 06 Feb 2018 Omigapil is still in phase I development for Muscular-dystrophies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top